These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20335149)

  • 1. [Preliminary study of XELOX regimen as the first-line chemotherapy in advanced or recurrent gastric cancer].
    Min N; He BF; Zhang LS; Liao H; Jia YZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):599-601. PubMed ID: 20335149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer.
    Quek R; Lim WT; Foo KF; Koo WH; A-Manaf A; Toh HC
    Acta Oncol; 2007; 46(7):1032-4. PubMed ID: 17917832
    [No Abstract]   [Full Text] [Related]  

  • 3. [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
    Dong NN; Wang MY; Zhang Q; Liu ZF
    Ai Zheng; 2009 Apr; 28(4):412-5. PubMed ID: 19622303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
    Luo HY; Xu RH; Wang F; Qiu MZ; Li YH; Li FH; Zhou ZW; Chen XQ
    Chemotherapy; 2010; 56(2):94-100. PubMed ID: 20357440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
    Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
    Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
    Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.
    Farhat FS; Kattan J; Ghosn MG
    Expert Rev Anticancer Ther; 2010 Apr; 10(4):541-8. PubMed ID: 20397919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
    Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
    BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
    Xiong HQ; Varadhachary GR; Blais JC; Hess KR; Abbruzzese JL; Wolff RA
    Cancer; 2008 Oct; 113(8):2046-52. PubMed ID: 18756532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
    Boige V; Raoul JL; Pignon JP; Bouché O; Blanc JF; Dahan L; Jouve JL; Dupouy N; Ducreux M;
    Br J Cancer; 2007 Oct; 97(7):862-7. PubMed ID: 17876335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer].
    Zhao Q; Li Y; Tan BB; Tian Y; Jiao ZK; Zhao XF; Zhang ZD; Wang D; Yang PG
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):773-7. PubMed ID: 24378101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A pilot study of combined chemotherapy using methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) for advanced or recurrent gastric cancer].
    Yamamura Y; Kodera Y; Kito T
    Gan To Kagaku Ryoho; 1995 Sep; 22(10):1407-10. PubMed ID: 7668879
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
    Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
    Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer.
    Baek YH; Choi SR; Jang JS; Roh MH; Lee JH; Won JJ; Lee CM
    Hepatogastroenterology; 2011; 58(105):251-6. PubMed ID: 21510324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of mitomycin C, cisplatin and 5-fluorouracil for advanced and recurrent gastric cancer.
    Kikuyama S; Inada T; Oyama R; Ogata Y
    Anticancer Res; 2002; 22(6B):3633-6. PubMed ID: 12552968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
    Zhang CX; Huang S; Xu N; Fang JW; Shen P; Bao YH; Mou BH; Shi MG; Zhong XL; Xiong PJ
    Anticancer Drugs; 2007 Jun; 18(5):581-6. PubMed ID: 17414627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence.
    Yuan ST; Wang FL; Liu N; Liu YH; Liu SG; Huang Y; Li YQ; Liu XB; Zhang Y; Li WH; Yu J; Zhang JD
    Am J Clin Oncol; 2015 Apr; 38(2):130-4. PubMed ID: 23608834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute.
    Sun LB; Zhao GJ; Ding DY; Song B; Hou RZ; Li YC
    World J Surg Oncol; 2014 Sep; 12():280. PubMed ID: 25200958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.